Interaction Checker

Pazopanib : interactions médicamenteuses

Pazopanib (Votrient) présente 257 interactions documentées dans les notices FDA et les fiches d'information que nous indexons : 148 de niveau majeur, 107 de niveau modéré, 2 de niveau mineur et 0 cas où une notice ne signale aucune interaction significative. Chaque entrée ci-dessous cite la phrase sur laquelle elle repose. Cette page consacrée à un médicament est un point de départ, pas un verdict sur votre situation.

Interactions d'après la notice

Interactions majeures (148)

  • Abrocitinibinhibiteur de JAKMajeure

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (notice Pazopanib, Interactions médicamenteuses)

  • AlfuzosinealphabloquantMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • AmiodaroneantiarythmiqueMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • Amitriptylineantidépresseur tricycliqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Anagrélidemédicament allongeant l'intervalle QTMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Antiacides (Tums, Maalox, Mylanta)Produits sans ordonnanceMajeure

    If concomitant administration with a gastric acid-reducing agent cannot be avoided, consider short-acting antacids in place of PPIs and H2-receptor antagonists. (notice Pazopanib, Interactions médicamenteuses)

  • Aprépitantinhibiteur du CYP3A4Majeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • Armodafinilstimulant du SNCMajeure

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (notice Pazopanib, Interactions médicamenteuses)

  • AsénapineantipsychotiqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • AtazanavirantirétroviralMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • Azithromycineantibiotique macrolideMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Bicarbonate de sodiumantiacideMajeure

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (notice Pazopanib, Interactions médicamenteuses)

  • Bosentaninducteur du CYP3A4Majeure

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (notice Pazopanib, Interactions médicamenteuses)

  • CarbamazépineanticonvulsivantMajeure

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (notice Pazopanib, Interactions médicamenteuses)

  • CénobamateanticonvulsivantMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • ChloroquineantipaludiqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • ChlorpromazineantipsychotiqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • CiclosporineimmunosuppresseurMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • Cimétidineantihistaminique H2Majeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • CiprofloxacinefluoroquinoloneMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • CitalopramISRSMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Clarithromycineantibiotique macrolideMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • ClobazambenzodiazépineMajeure

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (notice Pazopanib, Interactions médicamenteuses)

  • ClozapineantipsychotiqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • DarunavirantirétroviralMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • Darunavir et cobicistatantirétroviralMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • Déférasiroxsupplément de ferMajeure

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (notice Pazopanib, Interactions médicamenteuses)

  • Deutétrabénazineinhibiteur de VMAT2Majeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • DexaméthasonecorticoïdeMajeure

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (notice Pazopanib, Interactions médicamenteuses)

  • Dexlansoprazoleinhibiteur de la pompe à protons (IPP)Majeure

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (notice Pazopanib, Interactions médicamenteuses)

  • Dextrométhorphane et quinidinemédicament sérotoninergiqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Diltiazeminhibiteur calciqueMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • DisopyramideantiarythmiqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • DofétilideantiarythmiqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • DronédaroneantiarythmiqueMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • Dropéridolantagoniste de la dopamineMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • ÉfavirenzantirétroviralMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • Éfavirenz, lamivudine et ténofovirantirétroviralMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • Elvitégravir, cobicistat, emtricitabine et ténofovirantirétroviralMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • Érythromycineantibiotique macrolideMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • EscitalopramISRSMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • EslicarbazépineanticonvulsivantMajeure

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (notice Pazopanib, Interactions médicamenteuses)

  • Ésoméprazoleinhibiteur de la pompe à protons (IPP)Majeure

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (notice Pazopanib, Interactions médicamenteuses)

  • ÉtravirineantirétroviralMajeure

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (notice Pazopanib, Interactions médicamenteuses)

  • ÉvérolimusimmunosuppresseurMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • Famotidineantihistaminique H2Majeure

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (notice Pazopanib, Interactions médicamenteuses)

  • FingolimodimmunosuppresseurMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • FlécaïnideantiarythmiqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Flibansérinedépresseur du SNCMajeure

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (notice Pazopanib, Interactions médicamenteuses)

  • Fluconazoleantifongique azoléMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • FluoxétineISRSMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • FosamprénavirantirétroviralMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • Fosaprépitantinhibiteur du CYP3A4Majeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • FosphénytoïneanticonvulsivantMajeure

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (notice Pazopanib, Interactions médicamenteuses)

  • Granisétronmédicament allongeant l'intervalle QTMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • GriséofulvineantifongiqueMajeure

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (notice Pazopanib, Interactions médicamenteuses)

  • HalopéridolantipsychotiqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Hydroxychloroquinemédicament allongeant l'intervalle QTMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • HydroxyzineantihistaminiqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Ibuprofène et famotidineAINSMajeure

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (notice Pazopanib, Interactions médicamenteuses)

  • IbutilideantiarythmiqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • IlopéridoneantipsychotiqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Imatinibinhibiteur du CYP3A4Majeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • IsoniazideantibiotiqueMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • Itraconazoleantifongique azoléMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • Ivacaftorinhibiteur du CYP3A4Majeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • Kétoconazoleantifongique azoléMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • Lansoprazoleinhibiteur de la pompe à protons (IPP)Majeure

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (notice Pazopanib, Interactions médicamenteuses)

  • Lapatinibinhibiteur de la glycoprotéine PMajeure

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (notice Pazopanib, Interactions médicamenteuses)

  • Lédipasvir et sofosbuvirantiviralMajeure

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (notice Pazopanib, Interactions médicamenteuses)

  • LénacapavirantirétroviralMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • LévofloxacinefluoroquinoloneMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Lopéramidemédicament allongeant l'intervalle QTMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Lopinavir et ritonavirantirétroviralMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • Lorlatinibinducteur du CYP3A4Majeure

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (notice Pazopanib, Interactions médicamenteuses)

  • MéthadoneopioïdeMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Mifépristoneinhibiteur du CYP3A4Majeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • Mirabégronagoniste bêta-adrénergiqueMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • Mitapivatinducteur du CYP3A4Majeure

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (notice Pazopanib, Interactions médicamenteuses)

  • Mitotaneinducteur du CYP3A4Majeure

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (notice Pazopanib, Interactions médicamenteuses)

  • Modafinilstimulant du SNCMajeure

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (notice Pazopanib, Interactions médicamenteuses)

  • MoxifloxacinefluoroquinoloneMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Nafcillineantibiotique de la famille des pénicillinesMajeure

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (notice Pazopanib, Interactions médicamenteuses)

  • Naproxène et ésoméprazoleAINSMajeure

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (notice Pazopanib, Interactions médicamenteuses)

  • NéfazodoneantidépresseurMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • NévirapineantirétroviralMajeure

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (notice Pazopanib, Interactions médicamenteuses)

  • Nilotinibmédicament allongeant l'intervalle QTMajeure

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (notice Pazopanib, Interactions médicamenteuses)

  • Nirmatrelvir et ritonavirantiviralMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • Nizatidineantihistaminique H2Majeure

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (notice Pazopanib, Interactions médicamenteuses)

  • OfloxacinefluoroquinoloneMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Olanzapine et fluoxétineantipsychotiqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Oméprazoleinhibiteur de la pompe à protons (IPP)Majeure

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (notice Pazopanib, Interactions médicamenteuses)

  • Oméprazole et bicarbonate de sodiuminhibiteur de la pompe à protons (IPP)Majeure

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (notice Pazopanib, Interactions médicamenteuses)

  • Ondansétronmédicament allongeant l'intervalle QTMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • OxcarbazépineanticonvulsivantMajeure

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (notice Pazopanib, Interactions médicamenteuses)

  • Palbociclibinhibiteur du CYP3A4Majeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • PalipéridoneantipsychotiqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Pantoprazoleinhibiteur de la pompe à protons (IPP)Majeure

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (notice Pazopanib, Interactions médicamenteuses)

  • Pentamidinemédicament allongeant l'intervalle QTMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • PérampanelanticonvulsivantMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • PhénobarbitalbarbituriqueMajeure

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (notice Pazopanib, Interactions médicamenteuses)

  • Phentermine et topiramatestimulant du SNCMajeure

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (notice Pazopanib, Interactions médicamenteuses)

  • PhénytoïneanticonvulsivantMajeure

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (notice Pazopanib, Interactions médicamenteuses)

  • PimavansérineantipsychotiqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • PimozideantipsychotiqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Pitolisantmédicament allongeant l'intervalle QTMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Posaconazoleantifongique azoléMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • PrimidoneanticonvulsivantMajeure

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (notice Pazopanib, Interactions médicamenteuses)

  • ProcaïnamideantiarythmiqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • ProméthazineantihistaminiqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Prométhazine et codéineopioïdeMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Prométhazine et dextrométhorphaneantihistaminiqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • PropafénoneantiarythmiqueMajeure

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (notice Pazopanib, Interactions médicamenteuses)

  • QuétiapineantipsychotiqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • QuinidineantiarythmiqueMajeure

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (notice Pazopanib, Interactions médicamenteuses)

  • QuinineantipaludiqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Rabéprazoleinhibiteur de la pompe à protons (IPP)Majeure

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (notice Pazopanib, Interactions médicamenteuses)

  • Ranitidineantihistaminique H2Majeure

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (notice Pazopanib, Interactions médicamenteuses)

  • Ranolazinemédicament allongeant l'intervalle QTMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • RifabutineantibiotiqueMajeure

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (notice Pazopanib, Interactions médicamenteuses)

  • RifampicineantibiotiqueMajeure

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (notice Pazopanib, Interactions médicamenteuses)

  • RifapentineantibiotiqueMajeure

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (notice Pazopanib, Interactions médicamenteuses)

  • RispéridoneantipsychotiqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • RitonavirantirétroviralMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • Sofosbuvir et velpatasvirantiviralMajeure

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (notice Pazopanib, Interactions médicamenteuses)

  • SolifénacineanticholinergiqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • SotalolbêtabloquantMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Suvorexantsédatif-hypnotiqueMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • Suzétrigineinducteur du CYP3A4Majeure

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (notice Pazopanib, Interactions médicamenteuses)

  • TacrolimusimmunosuppresseurMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Tamoxifènemodulateur sélectif des récepteurs aux estrogènesMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Tétrabénazineinhibiteur de VMAT2Majeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • ThioridazineantipsychotiqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Ticagrélorantiagrégant plaquettaireMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • ToltérodineanticholinergiqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • TopiramateanticonvulsivantMajeure

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (notice Pazopanib, Interactions médicamenteuses)

  • Torémifènemodulateur sélectif des récepteurs aux estrogènesMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • TramadolopioïdeMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Tramadol et paracétamolopioïdeMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • TrazodoneantidépresseurMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Trioxyde d'arsenicmédicament allongeant l'intervalle QTMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Valbénazineinhibiteur de VMAT2Majeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Vardénafilinhibiteur de la PDE5Majeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • VenlafaxineIRSNaMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • Vérapamilinhibiteur calciqueMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • Voriconazoleantifongique azoléMajeure

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (notice Pazopanib, Interactions médicamenteuses)

  • ZiprasidoneantipsychotiqueMajeure

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (notice Pazopanib, Interactions médicamenteuses)

  • ZonisamideanticonvulsivantMajeure

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (notice Pazopanib, Interactions médicamenteuses)

Interactions modérées (107)

  • AcébutololbêtabloquantModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Acide étacryniquediurétique de l'anseModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • AdénosineantiarythmiqueModérée

    Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (notice Pazopanib, Mises en garde et précautions)

  • AliskirèneantihypertenseurModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Amiloridediurétique épargneur de potassiumModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Amlodipineinhibiteur calcique dihydropyridiniqueModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Amlodipine et atorvastatineinhibiteur calcique dihydropyridiniqueModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Amlodipine et bénazéprilinhibiteur calcique dihydropyridiniqueModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Amlodipine et olmésartaninhibiteur calcique dihydropyridiniqueModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Amlodipine et valsartaninhibiteur calcique dihydropyridiniqueModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • AténololbêtabloquantModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Aténolol et chlortalidonebêtabloquantModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • AtorvastatinestatineModérée

    Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (notice Pazopanib, Mises en garde et précautions)

  • Azilsartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Bénazéprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Bénazépril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • BétaxololbêtabloquantModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • BisoprololbêtabloquantModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Bisoprolol et hydrochlorothiazidebêtabloquantModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Candésartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Candésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Captoprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • CarvédilolbêtabloquantModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Chlorothiazidediurétique thiazidiqueModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Chlortalidonediurétique thiazidiqueModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Clonidineagoniste alpha-adrénergiqueModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Digoxineglycoside digitaliqueModérée

    Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (notice Pazopanib, Mises en garde et précautions)

  • Dinitrate d'isosorbide et hydralazinedérivé nitréModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • DoxazosinealphabloquantModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Énalaprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Énalapril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Énalaprilateinhibiteur de l'enzyme de conversion (IEC)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Éplérénoneantagoniste de l'aldostéroneModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • EsmololbêtabloquantModérée

    Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (notice Pazopanib, Mises en garde et précautions)

  • Ézétimibe et simvastatinestatineModérée

    Concomitant Use of Simvastatin Concomitant use of VOTRIENT and simvastatin increases the risk of ALT elevations [see Drug Interactions (7.3)] . (notice Pazopanib, Mises en garde et précautions)

  • Félodipineinhibiteur calcique dihydropyridiniqueModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • FluvastatinestatineModérée

    Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (notice Pazopanib, Mises en garde et précautions)

  • Fosinoprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Fosinopril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Furosémidediurétique de l'anseModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Guanfacineagoniste alpha-adrénergiqueModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • HydralazinevasodilatateurModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Hydrochlorothiazidediurétique thiazidiqueModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Indapamidediurétique thiazidiqueModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Irbésartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Irbésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Isradipineinhibiteur calcique dihydropyridiniqueModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • LabétalolbêtabloquantModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Lévothyroxinehormone thyroïdienneModérée

    Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Lévothyroxine et liothyroninehormone thyroïdienneModérée

    Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Lidocaïneanesthésique localModérée

    Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (notice Pazopanib, Mises en garde et précautions)

  • Lidocaïne et prilocaïneanesthésique localModérée

    Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (notice Pazopanib, Mises en garde et précautions)

  • Liothyroninehormone thyroïdienneModérée

    Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Lisinoprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Lisinopril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Lofexidineagoniste alpha-adrénergiqueModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • LomitapideModérée

    …Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology (12.3) ] . (notice Lomitapide, Interactions médicamenteuses)

  • Losartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Losartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • LovastatinestatineModérée

    Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (notice Pazopanib, Mises en garde et précautions)

  • MécamylamineantihypertenseurModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • MéthyldopaantihypertenseurModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Métolazonediurétique thiazidiqueModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • MétoprololbêtabloquantModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Métoprolol et hydrochlorothiazidebêtabloquantModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • MexilétineantiarythmiqueModérée

    Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (notice Pazopanib, Mises en garde et précautions)

  • MinoxidilvasodilatateurModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Moexiprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • NadololbêtabloquantModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • NébivololbêtabloquantModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Nicardipineinhibiteur calcique dihydropyridiniqueModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Nifédipineinhibiteur calcique dihydropyridiniqueModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Nisoldipineinhibiteur calcique dihydropyridiniqueModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Nitroprussiate de sodiumvasodilatateurModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Olmésartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Olmésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Olmésartan, amlodipine et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • PémétrexedantimétaboliteModérée

    Clinical trials of VOTRIENT in combination with pemetrexed and lapatinib were terminated early due to increased toxicity and mortality. (notice Pazopanib, Mises en garde et précautions)

  • Périndoprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • PhénoxybenzaminealphabloquantModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • PindololbêtabloquantModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • PitavastatinestatineModérée

    Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (notice Pazopanib, Mises en garde et précautions)

  • PravastatinestatineModérée

    Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (notice Pazopanib, Mises en garde et précautions)

  • PrazosinealphabloquantModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • PropranololbêtabloquantModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • PropylthiouracileantithyroïdienModérée

    Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Quinaprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Quinapril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Ramiprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • RosuvastatinestatineModérée

    Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (notice Pazopanib, Mises en garde et précautions)

  • Sacubitril et valsartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • SimvastatinestatineModérée

    Concomitant Use of Simvastatin Concomitant use of VOTRIENT and simvastatin increases the risk of ALT elevations [see Drug Interactions (7.3)] . (notice Pazopanib, Mises en garde et précautions)

  • Spironolactoneantagoniste de l'aldostéroneModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Spironolactone et hydrochlorothiazideantagoniste de l'aldostéroneModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Telmisartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Telmisartan et amlodipineantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Telmisartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • TérazosinealphabloquantModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Tériparatidehormone thyroïdienneModérée

    Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • ThiamazoleantithyroïdienModérée

    Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • TizanidinemyorelaxantModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Torasémidediurétique de l'anseModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Trandolaprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Triamtérènediurétique épargneur de potassiumModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Triamtérène et hydrochlorothiazidediurétique épargneur de potassiumModérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Valsartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

  • Valsartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (notice Pazopanib, Mises en garde et précautions)

Mentions mineures (2)

  • BévacizumabMineure

    Thrombotic Microangiopathy Thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), occurred in clinical trials of VOTRIENT as monotherapy, in combination with bevacizumab, and in combination with topotecan. (notice Pazopanib, Mises en garde et précautions)

  • TopotécanMineure

    Thrombotic Microangiopathy Thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), occurred in clinical trials of VOTRIENT as monotherapy, in combination with bevacizumab, and in combination with topotecan. (notice Pazopanib, Mises en garde et précautions)

Vérifiez Pazopanib avec tout ce que vous prenez. Ajoutez votre liste complète ; toutes les paires sont vérifiées en une fois.

Ouvrir dans le vérificateur

Ceci n'est pas un avis médical. Le niveau de gravité reflète la formulation de la notice, pas votre situation. Une alerte « majeure » peut être courante sous surveillance et une alerte « mineure » peut compter à forte dose. Demandez conseil à un pharmacien.